Rectal cancer: Poster Session Review
|
|
- Alyson Clark
- 5 years ago
- Views:
Transcription
1 AIOM PostASCO GI Roma, 5-6 febbraio 2016 Rectal cancer: Poster Session Review Sara Lonardi SS Trattamento Multidisciplinare Tumori Colorettali - UOC Oncologia Medica 1 Dipartimento di Oncologia Clinica e Sperimentale Istituto Oncologico Veneto IRCCS, Padova
2 Rectal Cancer Poster Session Estimation of risk Combined-modality treatment Prognostic factors Fields of improvement
3 Rectal Cancer Poster Session Estimation of risk (#716) Combined-modality treatment Prognostic factors Fields of improvement
4 Nomogram for prediction of response to neoadjuvant CRT Methods: Data from 309 patients enrolled in FOWARC study. Pre-treatment clinical parameters collected to build a nomogram for pcr Zhang J et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 716)
5 Univariate/multivariate analysis of pretreatment parameters Zhang J et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 716)
6 Nomogram for prediction of response to neoadjuvant CRT Zhang J et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 716)
7 Rectal Cancer Poster Session Estimation of risk (#716) Combined-modality treatment (#691, #657, #677, #737, #713) Prognostic factors Fields of improvement
8 Same overall survival Better local control Reduced toxicity
9 Treatment patterns in the US over the past decade Stage II/III rectal adenocarcinoma within the National Cancer Data Base undergoing surgery between were analyzed (n=66197). Sineshaw HM et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 691)
10 OS in st II-III rectal cancer by treatment 5-yr OS: NACRT: 72.4% surgery and adj CRT: 70.9% surgery alone: 44.9% definitive CRT: 48.8% Sineshaw HM et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 691)
11 Effect of combined neoadjuvant chemoradiation on OS Stage II/III rectal adenocarcinoma within the National Cancer Data Base undergoing surgery between were analyzed (n=32978). Sun Z et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 657)
12 Effect of combined neoadjuvant chemoradiation on OS Stage II/III rectal adenocarcinoma within the National Cancer Data Base undergoing surgery between were analyzed. 62%, 69%, 71%, 74%, 5y-OS Sun Z et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 657)
13 Treatment impact on outcomes vs surgery alone Sun Z et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 657)
14 CRT impact on outcomes vs chemo/rt alone Sun Z et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 657)
15 Optimal timing for curative surgery after CRT Retrospective study on LARC (ct3-4n0-2m0) receiving preoperative CRT followed by TME from 2003 to 2014, at 8 institutions in Korea (n=1786). Primary EP: to evaluate the period of highest downstaging and ypcr rates to determine the optimal timing for surgery after CRT. Downstaging rates peaked between 6 and 7 weeks and declined afterwards. ypcr rates increased from 5 to 6 weeks and decreased after 9 to 10 weeks. Kwak YK et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 677)
16 Optimal timing for curative surgery after CRT Complete tumor regression: 9.1% vs.13.2%, p = Sphincter preservation rates: 89.9% vs. 92.4%, p = No statistically significant difference regarding OS and DFS Kwak YK et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 677)
17 Surveillance and timing of surgical resection after CRT Retrospective study on LARC (ct3-4n0-2m0) receiving preoperative CRT followed by TME from 2003 to 2011, single Institution (n=171). Pachón Olmos V et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 737)
18 Timing of surgical resection after CRT and outcome Pachón Olmos V et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 737)
19 pcr rates after neoadj tx: an analysis of the NCDB NCDB Retrospective study on non-metastatic rectal cancer ( ) who underwent neoadjuvant therapy followed by surgical resection (n=7,859) The incidence of pcr was associated with favorable tumor factors (size, grade, T classification), demographics (insurance status) as well as treatment factors (time between radiation and surgery and institutional volume). Lorimer PD et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 713)
20 Rectal Cancer Poster Session Estimation of risk (#716) Combined-modality treatment (#691, #657, #677, #737, #713) Prognostic factors (#575, #661, #693) Fields of improvement
21 Host immune response prognostic role after CRT mrna and protein expression of the B- and T-cell chemokines CXCL13 and CXCL9 in LARC undergoing preoperative CRT and surgery (n=77) Intratumoral mrna expression levels of the T-cell activator CXCL9 (p < 0.001) as well as the B-cell chemokine CXCL13 (p < 0.01) were inversely correlated with the development of distant metastasis. Patients with high CXCL9 (p < ) or CXCL13 expression (p < 0.01) had a significantly prolonged DFS. Sprenger et al,j Clin Oncol 34, 2016 (suppl 4S; abstr 575)
22 Integration of strategies in rectal cancer Pts treated with ncrt followed by curative radical surgery (n=141) LPLN before ncrt: 16 pts. Group 1: 7 pts showing disappearance of LPLN after ncrt Group 2 9 pts showing persistance of LPLN after ncrt Group 1: similar oncologic outcome with yptnm stage II (P = ). Group 2: tendency of worse oncologic outcome than yptnm stage III (P = 0.135) P = Kim H et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 661)
23 Outcome prediction by ctnm stage vs yptnm stage Pts treated with ncrt followed by curative radical surgery (n=141) ctnm stage did not demonstrate any correlation with DFS (cii % vs ciii %, P = 0.266). Kim H et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 693)
24 Outcome prediction by ctnm stage vs yptnm stage 3-year DFS by yptnm: - ypi, 87.9%; - ypii, 67.8%; - ypiii, 53.3% Kim H et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 693)
25 Rectal Cancer Poster Session Estimation of risk (#716) Combined-modality treatment (#691, #657, #677, #737, #713) Prognostic factors (#575, #661, #693) Fields of improvement (#502, #673)
26 Fields of improvement Optimize local control Acute and late toxicities Reduce distant metastases Improved survival Clinical benefit
27 Risk/benefit balance improvement intensification of concurrent CRT Acute and late toxicities Neoadjuvant / Consolidation / adjuvant CT Clinical benefit
28 Phase II trial of perioperative chemotherapy using FOLFOX with panitumumab for LARC Multicenter phase II trial on clinical stage III, kras wt rectal cancer Primary outcome: response rate of the primary lesion measured by T2 weighted sagittal image of magnetic resonance imaging. Ota M et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 502)
29 Phase II trial of perioperative chemotherapy using FOLFOX with panitumumab for LARC Between January 2012 and December 2014, 42 out of 43 patients completed preoperative chemotherapy There was no progressive disease in the 42 patients All of the 43 participants underwent resection without mortality or severe complications. Ota M et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 502)
30 Induction treatment with FOLFOXIRI + bev CRT + bev: The phase II TRUST trial LARC at < 12 cm from the anal verge N+ or ct4 or high risk ct3 (MRI criteria) Primary endpoint is 2-year disease-free survival (DFS). Vivaldi C et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 673)
31 Patients characteristics Vivaldi C et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 673)
32 Induction treatment toxicities Vivaldi C et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 673)
33 Induction treatment toxicities Vivaldi C et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 673)
34 Concomitant chemoradiation Vivaldi C et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 673)
35 Activity Vivaldi C et al, J Clin Oncol 34, 2016 (suppl 4S; abstr 673)
36
Carcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationPancreas Cancer ASCO Poster Review
Bologna, 9 Febbraio 2019 AIOM POST ASCO GI REVIEW Updates and News from the GI Cancers Symposium in San Francisco Pancreas Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Medica Fondazione Policlinico
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationASCO GI 2018 Rectal Cancer Poster Review Filippo Pietrantonio INT Milan
ASCO GI 2018 Rectal Cancer Poster Review Filippo Pietrantonio INT Milan Rome, 16 February 18 AGENDA rectal cancer data - Staging - Prognostic Factors - Management strategies Staging AJCC 7 edition staging:
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationMeta analysis in Rectal Cancer
Meta analysis in Rectal Cancer Dr. Monica Irukulla Professor and Head Department of Radiation Oncology Nizam s Institute of Medical Sciences hyderabad Areas of meta analysis in rectal cancers Epidemiology
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationManagement of early rectal cancer: Any role for adjuvant chemotherapy
Management of early rectal cancer: Any role for adjuvant chemotherapy Andrés Cervantes Professor of Medicine CURRENTS CONCEPTS IN RECTAL CANCER DIAGNOSIS AND THERAPY TME surgery Optimal staging by MRI
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Valencia May 2018 State of the art: Standards of care in preoperative treatment for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures:
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationBiomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin)
Recent advances in the management of CRC II 2017/12/17 (Sun.) 10:10-11:00 Biomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin) Department of Clinical
More informationAmerican College of Surgeons Clinical Research Program Surgical Investigators Webinar. November 17, Moderator: Y. Nancy You, M.D.
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director American College of Surgeons Clinical Research Program Surgical Investigators Webinar November 17, 2017 Moderator:
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationRectal Cancer : Curative treatment without surgery
Rectal Cancer : Curative treatment without surgery Dieter Hahnloser dieter.hahnloser@chuv.ch CHUV University Hospital Lausanne Switzerland Reasons for intervention (surgery) Cure Live longer Feel better
More informationThe Role Of The Post-CRT MRI In Assessing Response
Low Rectal Cancer: Is It Safe To Change The Plane Of Surgery? The Role Of The Post-CRT MRI In Assessing Response Nick Battersby, Mit Dattani, Nick West, Graham Branagan, Mark Gudgeon, Phil Quirke, Paris
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationEarly Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh
Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationRectal Cancer: Classic Hits
Rectal Cancer: Classic Hits Charles M. Friel, MD Associate Professor of Surgery Section of Colon and Rectal Surgery University of Virginia September 28, 2016 None Disclosures 1 Objectives Review the Classic
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 State of the art: Radio- /chemotherapy for rectal cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationL impatto dell imaging sulla definizione della strategia terapeutica
GISCoR L impatto dell imaging sulla definizione della strategia terapeutica M. Galeandro U.C. Radioterapia Oncologica ASMN-IRCCS Reggio Emilia 14 Novembre 2014 Rectal Cancer TNM AJCC-7 th edition 2010
More informationOpportunity for palliative care Research
Opportunity for palliative care Research Role of Radiotherapy in Multidisciplinary Management of Rectal Cancers Dr Sushmita Pathy Associate Professor Department of Radiation Oncology Dr BRA Institute Rotary
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationChemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
More informationRestaging after neoadjuvant chemoradiation in rectal cancers: is histology the key in patient selection?
Original Article Restaging after neoadjuvant chemoradiation in rectal cancers: is histology the key in patient selection? Nitin Singhal 1, Karthik Vallam 1, Reena Engineer 2, Vikas Ostwal 3, Supreeta Arya
More informationOriginal Article The value of lymph node ratio in the prediction of rectal cancer patient survival after preoperative chemoradiotherapy
Int J Clin Exp Pathol 2018;11(12):5992-6001 www.ijcep.com /ISSN:1936-2625/IJCEP0086231 Original Article The value of lymph node ratio in the prediction of rectal cancer patient survival after preoperative
More informationCOLORECTAL CANCER. Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program
COLORECTAL CANCER Bert H. O Neil, MD Jackie and Joseph Cusick Professor of Oncology Director, GI Malignancies and Phase I Program Rectal Cancer Adjuvant therapy No single study specific to rectal cancer
More informationNing Li, Jing Jin, Jing Yu, Shuai Li, Yuan Tang, Hua Ren, Wenyang Liu, Shulian Wang, Yueping Liu, Yongwen Song, Hui Fang, Zihao Yu, Yexiong Li
Original Article Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypi stage after neoadjuvant chemo-radiotherapy versus de novo stage pi cohort: A propensity score-matched
More informationASCO GI 2018: Rectal Cancer Take home messages
AIOM Post-ASCO GI 2018 Roma 17 febbraio 2018 ASCO GI 2018: Rectal Cancer Take home messages Carmelo Pozzo UOC di Oncologia Generale Fondazione di Ricerca e Cura Giovanni Paolo II UCSC, Campobasso Current
More informationA clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
Med Oncol (2014) 31:839 DOI 10.1007/s12032-014-0839-1 ORIGINAL PAPER A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Michaela Jung Annica Holmqvist Xiao-Feng Sun
More informationCa Cardias e Stomaco: le diversita e le terapie
XXII Riunione Nazionale I.T.M.O. Ca Cardias e Stomaco: le diversita e le terapie Maria Di Bartolomeo s.s. Oncologia Medica Gastroenterologica Fondazione IRCCS Istituto Nazionale Tumori Milano OUTLINE History
More informationGrandangolo in Radioterapia Oncologica. D. Genovesi; F. Perro/ Is1tuto di Radioterapia Oncologica CHIETI
Grandangolo in Radioterapia Oncologica D. Genovesi; F. Perro/ Is1tuto di Radioterapia Oncologica CHIETI www.radioterapia.unich.it TOPICS ü ESOFAGO & GIUNZIONE ESOFAGO- GASTRICA ü STOMACO ü RETTO ü ANO
More informationAmerican College of Surgeons Clinical Research Program Surgical Investigators Webinar. October 5, Moderator: Y. Nancy You, M.D.
American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director American College of Surgeons Clinical Research Program Surgical Investigators Webinar October 5, 2018 Moderator:
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationTreatment of Locally Advanced Rectal Cancer: Current Concepts
Treatment of Locally Advanced Rectal Cancer: Current Concepts James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationCarcinoma renale (I): Posters Review. Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano
Carcinoma renale (I): Posters Review Elena Verzoni Oncologia Medica 1 SS.Oncologia Genitourinaria Fondazione IRCCS Istituto Nazionale Tumori Milano Agenda: Best Posters in Localized RCC Surgery: CN (#
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationEsophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment
Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer Center Preop Therapy in Esophageal and
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationUpdated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
Local Esophageal Cancer Summary Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationCase Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological Response
Case Reports in Surgery Volume 2015, Article ID 816491, 5 pages http://dx.doi.org/10.1155/2015/816491 Case Report 17-Week Delay Surgery after Chemoradiation in Rectal Cancer with Complete Pathological
More informationOral Communications. Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer
Prostata: Diagnosis and treatment of localized and locally advanced prostate cancer Oral Communications Elisa Zanardi UOC Clinica di Oncologia Medica Ospedale Policlinico San Martino Dipartimento di Medicina
More informationIntroduction. Approximately 40,000 patients are diagnosed with rectal. Original Article
Original Article Does a fine line exist between regional and metastatic pelvic lymph nodes in rectal cancer striking discordance between national guidelines and treatment recommendations by US radiation
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More information1. Background. increased sphincter preservation rate. Nonetheless, the 5- year disease-free survival and overall survival rates were
Gastroenterology Research and Practice Volume 2016, Article ID 7870815, 5 pages http://dx.doi.org/10.1155/2016/7870815 Research Article Does Extending the Waiting Time of Low-Rectal Cancer Surgery after
More informationPATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY
PATHOLOGIC FACTORS PROGNOSTIC OF SURVIVAL IN PATIENTS WITH GI TRACT AND PANCREATIC CARCINOMA TREATED WITH NEOADJUVANT THERAPY Jeannelyn S. Estrella, MD Department of Pathology The UT MD Anderson Cancer
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationASCO Poster Review PANCREATIC CANCER
ASCO Poster Review PANCREATIC CANCER Dr.ssa Michela Squadroni U.O. Oncologia Humanitas Gavazzeni Bergamo TOPICAL ISSUES Gemcitabine/Nab-paclitaxel and FOLFIRINOX comparison Neoadjuvant and perioperative
More informationLower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance
Original Article Lower lymph node yield following neoadjuvant therapy for rectal cancer has no clinical significance Dedrick Kok Hong Chan 1,2, Ker-Kan Tan 1,2 1 Division of Colorectal Surgery, University
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationRectal cancer with synchroneous liver mets: A challenging clinical case
ESMO Preceptorship Programme Rectal cancer Singapur November 2017 Rectal cancer with synchroneous liver mets: A challenging clinical case Andrés Cervantes Disclosures Consulting and advisory services,
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationCerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara
Cerebel trial Any impact on the clinical practice? Antonio Frassoldati Oncologia Clinica - Ferrara CNS metastases in HER2+ BC The proportion of patients with HER2+ advanced breast cancer who have CNS metastases
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationNeoadjuvant treatment Evolution and Current Status
Neoadjuvant treatment Evolution and Current Status Dr Andrew See Radiation Oncologist 2017 Rectal Cancer Symposium Friday 10 th November 2017 2 1 Major Randomised Trials Supporting Neoadjuvant CRT Trial
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationGI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?
GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationRevisione Oral Abstracts
Revisione Oral Abstracts Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi UPDATES and NEWS from the Genitourinary Cancers Symposium - Milano,
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationNeoplasie uroteliali Posters & oral presentations
UPDATES and NEWS from the Genitourinary Cancers Symposium 3 Marzo 2017, Milano Neoplasie uroteliali Posters & oral presentations Cristina Masini Oncologia Medica IRCCS-Arcispedale S.Maria Nuova - Reggio
More informationNeoadjuvant Conformal Chemoradiation with Induction Chemotherapy for Rectal Adenocarcinoma. A Prospective Observational Study
ORIGINAL PAPER Neoadjuvant Conformal Chemoradiation with Induction Chemotherapy for Rectal Adenocarcinoma. A Prospective Observational Study Zsolt Fekete 1, 2, Alina-Simona Muntean 2, Ştefan Hica 2, Alin
More informationLiver and Biliary Tract Cancers Critical Review
Liver and Biliary Tract Cancers Critical Review Lorenza Rimassa Oncologia Medica e Ematologia Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Critical review Oral presentations Melero
More information11/21/13 CEA: 1.7 WNL
Case Scenario 1 A 70 year-old white male presented to his primary care physician with a recent history of rectal bleeding. He was referred for imaging and a colonoscopy and was found to have adenocarcinoma.
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationESMO Preceptorship Programme
ESMO Preceptorship Programme Rectal Cancer Barcelona November 2016 Andreia Braz Pires Radiation Oncology Resident (3rd year) Instituto Português de Oncologia do Porto Francisco Gentil, EPE Low dose re-irradiation
More informationRole of MRI for Staging Rectal Cancer
Role of MRI for Staging Rectal Cancer High-resolution MRI has supplanted endoscopic ultrasound for staging rectal cancer. High-resolution MR images closely match histology and can show details such as
More informationRectal Cancer Update 2008 The Last 5 cm. Consensus Building
Rectal Cancer Update 2008 The Last 5 cm Consensus Building Case Distal Rectal Cancer 65 male physician Rectal mass: 5cm from anal verge, 1cm above sphincter? Imaging choice: CT vs MR vs ERUS? Adjuvant
More informationRectal Cancer. Rectal Cancer: The CCF perspective 16/11/2017. Meagan Costedio, MD, FACS, FASCRS. 38,220 new cases estimated in
Rectal Cancer: The CCF perspective Meagan Costedio, MD, FACS, FASCRS Medical Director Colorectal Surgery University Hospitals Ahuja Medical Center Associate Professor - Division of Colorectal Surgery Rectal
More informationResection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy
Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy Dr Chan Chung Yip MBBS, M.Med(Surgery), MD, FAMS, FRCSEd Senior Consultant and Head Department of Hepatopancreatobiliary
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationSan Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective. Disclosures
San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective January 18, 2011 Association of Northern California Oncologists Steven Chen, MD, MBA Chief, Breast Surgery University of
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCarcinoma colorettale: personalizzazione del trattamento
33 Incontro Oncologico del Triveneto Padova, Aprile 2017 Carcinoma colorettale: personalizzazione del trattamento Fotios Loupakis, MD PhD U.O.C. Oncologia Medica 1 Dipartimento di Oncologia Clinica e Sperimentale
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationState of the art: Standard(s) of radio/chemotherapy for rectal cancer
State of the art: Standard(s) of radio/chemotherapy for rectal cancer Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey Disclosure Advisory Board: Sanofi Oncology, Eli-
More informationDisclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
More informationRectal cancer management: a team sport The role of radiology and the multidisciplinary conference
Rectal cancer management: a team sport The role of radiology and the multidisciplinary conference W. Donald Buie MD MSc FRCSC Professor of Surgery and Oncology Department of Surgery University of Calgary
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationNEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah
NEOADJUVANT THERAPY IN CARCINOMA STOMACH Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah NEOADJUVANT THERAPY?! Few believers Limited evidence Many surgeons
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationDirk Arnold Lógica de proximidade à população
Doenca Contando metastatica já com 70 anos potencialmente de experiência no resecável: sector da saúde Tratamento igual para colon e para recto? 5 Hospitais Privados CUF 6 Clínicas de ambulatório CUF 6
More informationDifferential effect of concurrent chemotherapy regimen on clinical outcomes of preoperative chemoradiotherapy for locally advanced rectal cancer
JBUON 2019; 24(2): 470-478 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Differential effect of concurrent chemotherapy regimen on clinical outcomes
More information